Approved Drug Library (ADL)—also called the Approved Drug Compound Library, FDA‑Approved Drug Library, or FDA‑Approved Drug Compound Library—collects the active pharmaceutical ingredients of 2,818 drugs that have been approved for marketing by official regulatory agencies such as the FDA, EMA, or NMPA. It is especially suited to the earliest, high‑priority rounds of compound selection in drug‑screening campaigns. If researchers have established a screening platform and want to identify active drugs, the Beyotime Approved Drug Library is the first collection worth considering.
All of the compounds have undergone extensive and rigorous pre‑clinical and clinical studies; their bioactivity and safety are validated, their activities are well defined, and their targets are known. They can therefore be used for high‑throughput screening (HTS) and high‑content screening (HCS) and serve as an excellent drug‑repurposing tool, helping existing drugs find new targets and markedly accelerating drug‑development timelines.
Conventional new‑drug R&D—covering target validation, compound screening, candidate identification, pre‑clinical studies, and clinical trials—is time‑consuming and extremely costly. As good drug targets become scarcer and the safety‑and‑efficacy bar in clinical studies rises, the cost of developing new drugs has continued to climb, far surpassing the once‑cited “one billion dollars over ten years” threshold [1].
In recent years, drug repurposing (finding new uses for old drugs) has gained increasing attention from drug‑development and academic researchers alike. Thanks to advances in HTS/HCS platforms, the discovery of new biomarkers, and rapid progress in bioinformatics, marketed drugs—already proven for bioactivity, pharmacokinetics, safety, and bioavailability—can dramatically speed up target‑ or cell‑based drug‑development and optimization, cut costs and failure risk, and shorten development cycles [2].
Because compounds in the Approved Drug Library have well‑defined activities and known targets, many researchers use it to identify drugs for new indications, novel biological functions, or the pharmacological modulation of physiological and pathological processes; to explore combination therapies; and to screen small molecules that induce cell differentiation. Through single or combinatorial small‑molecule treatments, they have selected protocols that convert various somatic cells into induced pluripotent stem cells, neural progenitors, cardiomyocytes, and more—and even achieved in‑vivo differentiation with small‑molecule cocktails.
Library format
- 2,818 API compounds approved by the FDA (Food and Drug Administration), EMA (European Medicines Agency), NMPA (National Medical Products Administration), or other authoritative agencies.
- Compounds are supplied in DMSO in thirty‑six V‑bottom 96‑well plates, sealed with aluminum foil. Each plate carries a barcode for easy compound identification.
- Complete compound data are provided—including English name, CAS number, molecular weight, targets and signaling pathways, structure, IC₅₀, and activity description.
- Detailed compound list (Excel) (request from info@angenovo.no)
Quality and diversity
- Clinically validated bioactivity and safety.
- Diverse chemical structures with robust pharmacological effects and cell permeability.
- All compounds verified by NMR and HPLC/LC‑MS to ensure correct structure and high purity.
Research coverage
Includes agents relevant to oncology, cardiovascular disease, inflammation and immunity, neurology, respiratory disease, dermatology, endocrinology, and more.
Signaling pathways represented
Anti‑infection, Apoptosis, Autophagy, DNA Damage/Repair, GPCR, NF‑κB, PI3K/Akt/mTOR, JAK/STAT, Tyrosine Kinase/Adaptors, TGF‑β/Smad, MAPK/ERK, Metabolism, Proteases/Proteasome, Immunology/Inflammation, Microbiology/Virology, Neuroscience, Stem Cells, Membrane Transporters/Ion Channels, etc.
Convenient, flexible format
- Stored in V‑bottom 96‑well plates—compatible with automated instruments and multichannel pipettes, while minimizing dead volume.
- Columns 1 and 12 are empty for DMSO or other controls and to reduce edge effects in cell culture.
- For manual screening: with 36 plates total, screening 2–4 plates per person per day would complete one full round in roughly 9–18 working days.
Cost‑effective for large‑scale, low‑frequency screens
- All compounds at 10 mM in 10 µL.
- At a working concentration of 10 µM in a 200 µL 96‑well format, each library can be used for ~50 screens; in a 50 µL 384‑well format, for ~200 screens.
Storage Conditions:
- Store at –20 ºC for a minimum of 1 year;
- Store at –80 ºC for a minimum of 2 years.
Notes:
- Place 96-well plates in a well-sealed container with desiccant before freezing at the appropriate temperature.
- After each thaw, ensure the outside of the plate remains dry. You may use absorbent paper to wipe any moisture from the surface of the 96-well plate.
- Before removing the aluminum sealing film, be sure to bring the 96-well plate to room temperature and briefly centrifuge it (5000 rpm for 30 seconds). This prevents any residual liquid from clinging to the walls of the wells or the underside of the foil.
- Although the compounds in this approved drug library are clinically validated APIs with good stability and long shelf life, cold storage is still strongly recommended.
For research use only.
This product is intended for scientific research by qualified professionals.
Not for clinical diagnosis or treatment, not for food or drug use, and not for storage in residential settings.
